Baker McKenzie has advised argenx on its strategic collaboration and exclusive license agreement with Zai Lab for the development and commercialization of efgartigimod in Greater China, including mainland China, Hong Kong, Taiwan and Macau.
Through this collaboration, argenx will be able to expand the reach of efgartigimod in Greater China, as well as accelerate the number of autoimmune indications in clinical development. Under the terms of the agreement, Zai Lab will recruit Chinese patients to argenx’s global registrational trials for the development of efgartigimod. This will allow argenx to accelerate efgartigimod development by initiating multiple phase 2 proof-of-concept trials in new autoimmune indications.
Baker McKenzie, which acted as lead counsel on the transaction, fielded a cross-office, cross-practice team led by Partners Koen Vanhaerents (Corporate Finance, Belgium); Denis Segota (Corporate & Securities, New York); and Oren Livne (Corporate & Securities, New York). They were supported by a team comprised of Partners Thomas Rice (Corporate & Securities, New York); Clement Ngai (IP, Shanghai); Roel Meers (Corporate Finance, Brussels); Luc Meeus (Corporate Finance, Brussels); Dorothea Koo (M&A/Private Equity, Hong Kong) and Tracy Wut (M&A/Private Equity, Hong Kong); and associate Julia Schieber (IP, Zurich – pictured).